MRI in the driver’s seat: Scanners steer tumor-targeting virus inside the body

Cell-based therapies that exploit modified human cells to treat cancer have been a promising area of research, but issues remain. Specifically, the driver-less cells are difficult to target, especially in tissues deep in the body.

These therapies may gain a new sense of direction, however, thanks to an international team of researchers investigating whether the magnetic field of MRI scanners could be used to direct a tumor-smashing virus toward its target.

A recent preclinical study, published in Nature Communications, is offering an early glimpse at the technique’s potential.

“Our results suggest that it is possible to use a standard MRI scanner to naturally deliver cell-based therapies to both primary and secondary tumors which would normally be impossible to reach by injection,” said lead researcher Munitta Muthana, PhD, from the University of Sheffield’s Department of Oncology, in a statement.

Muthana and colleagues took macrophages carrying an oncolytic virus, Seprehvir, and magnetically labelled them with super-paramagnetic iron oxide nanoparticles (SPIOS). Using pulsed magnetic field gradients, the researchers were able to non-invasively steer the cells in the direction of tumor sites in mice.

By targeting the cells using SPIOs, the study demonstrated an eight-fold increase in the effects of the therapy.

“This not only increases the therapeutic efficacy but also decreases the risk of unwanted side effects,” said Muthana. “The beauty of using the MRI scanner to administer the therapy is that you can also use it for its original purpose providing a real-time image-guide to ensure the treatment has gone where it is needed.”

In addition to the University of Sheffield, the University of Florida and University College London also collaborated in the research.

Evan Godt
Evan Godt, Writer

Evan joined TriMed in 2011, writing primarily for Health Imaging. Prior to diving into medical journalism, Evan worked for the Nine Network of Public Media in St. Louis. He also has worked in public relations and education. Evan studied journalism at the University of Missouri, with an emphasis on broadcast media.

Around the web

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.